GlassScriptPhysician profile
Adrian L Pinzon
NPI 1114096013
$2,546.18
in general payments reported to CMS, 2019-2025
13 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $12.37 · 2021: $14.61 · 2022: $582 · 2023: $845 · 2024: $708 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.03 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,103.20 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $894.78 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $125.38 | 2023-2024 | |
| Inspire Medical Systems, INC. | $88.67 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $87.23 | 2019-2024 | Airsupra |
| Boston Scientific Corporation | $64.36 | 2022-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $33.07 | 2023-2024 | Shingrix |
| Exact Sciences Corporation | $30.22 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.44 | 2024 | |
| Abbott Laboratories | $23.94 | 2023 | Freestyle Libre 2 |
| Nevro Corp. | $23.64 | 2022 | |
| Medtronic, INC. | $18.57 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Pinzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.